[HTML][HTML] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
[HTML][HTML] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - Cell Host & Microbe, 2021 - Elsevier
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
[HTML][HTML] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - Cell Host & Microbe, 2021 - cell.com
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
[HTML][HTML] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - Cell Host & …, 2021 - ncbi.nlm.nih.gov
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - 2021 - cabidigitallibrary.org
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
[PDF][PDF] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, DH Fremont… - academia.edu
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet… - Cell Host and …, 2021 - profiles.wustl.edu
Liu et al. isolated 50 escape mutants to 19 monoclonal antibodies targeting the SARS-CoV-
2 spike using a VSV-SARS2 chimera. Some mutants (S477N) resist neutralization by …
2 spike using a VSV-SARS2 chimera. Some mutants (S477N) resist neutralization by …
[引用][C] Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - Cell Host & …, 2021 - cir.nii.ac.jp
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum
antibody neutralization | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
antibody neutralization | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Z Liu, LA VanBlargan, LM Bloyet… - Cell host & …, 2021 - pubmed.ncbi.nlm.nih.gov
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
Z Liu, LA VanBlargan, LM Bloyet, PW Rothlauf… - Cell Host & …, 2021 - europepmc.org
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …